Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1
Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse...
Neelapu, Sattva S.;Locke, Frederick L.;Bartlett, Nancy L.;Lekakis, Lazaros;Miklos, David;Jacobson, Caron A.;Braunschweig, Ira;Oluwole, Olalekan;Siddiqi, Tanya;Lin, Yi;Timmerman, John;Stiff, Patrick J.;Friedberg, Jonathan;Flinn, Ian;Goy, Andre;Smith, Mitchell;Deol, Abhinav;Farooq, Umar;McSweeney, Peter;Munoz, Javier;Avivi, Irit;Castro, Januario E.;Westin, Jason R.;Chavez, Julio C.;Ghobadi, Armin;Komanduri, Krishna V.;Levy, Ronald;Jacobsen, Eric D.;Reagan, Patrick;Bot, Adrian;Rossi, John M.;Navale, Lynn;Jiang, Yizhou;Aycock, Jeff S.;Elias, Meg;Wiezorek, Jeff;Go, William Y.;
2016-12-02 00:00:00
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngBloodUnpaywallhttp://www.deepdyve.com/lp/unpaywall/kte-c19-anti-cd19-car-t-cells-induces-complete-remissions-in-patients-axZPvBvZNe
Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1
Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
